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Abstract Increased osteocyte apoptosis, as the result of
estrogen deficiency, could play a role in the decrease of
bone mass and bone strength seen in postmenopausal
osteoporosis. We investigated whether treatment with ra-
loxifene of postmenopausal women with osteoporosis
affects osteocyte apoptosis. Transiliac bone biopsies were
obtained from 26 osteoporotic women at baseline and after
2 years of treatment with placebo or raloxifene. Immuno-
histochemical detection of cleaved caspase-3 was per-
formed on sections from nondecalcified bone biopsies to
visualize apoptosis. In the trabecular bone total osteocytes,
positively stained osteocytes and empty lacunae were
counted and percent positive cells and percent empty
lacunae determined. Statistical evaluation was performed
by Wilcoxon’s paired t-test and Spearman’s rank correla-
tions. There was no significant difference in percentage
positive osteocytes between baseline and follow-up biop-
sies in both the placebo and the raloxifene groups. The
percentage empty lacunae increased significantly in the
placebo group (11.20 ± 1.43 vs. 9.00 ± 2.25, P = 0.014)
but not in the raloxifene group. At baseline in both groups
combined, there was a negative correlation between indices
of bone remodeling and the percentage positive osteocytes
(bone formation rate/bone volume r = 0.67, P = 0.001).
We found no direct evidence for an effect of raloxifene
treatment on osteocyte apoptosis, but small effects of
raloxifene treatment cannot be excluded. The percent of
apoptotic osteocytes was dependent on the level of bone
remodeling in an individual.
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Osteocytes play a key role in the maintenance of bone mass
and structure. The main function of osteocytes is to sense
mechanical stress in the bone [1]. Osteocytes respond to
this with the production of nitric oxide, prostaglandins, and
other factors which are believed to restrain osteoclastic
bone resorption or promote bone formation [2, 3]. A
putative second role of osteocytes is to direct bone
remodeling to foci of microdamage. Osteocyte apoptosis
around the site of microdamage attracts bone remodeling
cells, which resorb the damaged bone and replace it with
new mechanically competent bone [4, 5].
Postmenopausal osteoporosis generally results in a
decrease in bone mineral density (BMD) and a higher
susceptibility for osteoporotic fractures. It is characterized
by high bone remodeling, with bone resorption exceeding
bone formation. Estrogen deficiency results in an increase
in the recruitment and activity of both osteoblasts and os-
teoclasts. It also leads to increased osteoclast survival,
while the life span of the osteoblast is decreased [6, 7].
Recently it has been shown both in humans and in rats that
estrogen deficiency also leads to increased osteocyte
apoptosis [8, 9]. The resulting decrease in osteocyte num-
ber could, in time, impair the response of bone to
mechanical stress and lead to an accumulation of micro-
damage. Therefore, it would be of interest to know whether
therapies aimed at reducing postmenopausal bone loss
affect the survival of osteocytes.
H. W. van Essen (&)  P. J. Holzmann  P. Lips
Department of Endocrinology, VU University Medical Center,
1007 MB Amsterdam, The Netherlands
e-mail: hw.vanessen@vumc.nl
M. A. Blankenstein  N. Bravenboer
Department of Clinical Chemistry, VU University Medical
Center, 1007 MB Amsterdam, The Netherlands
123
Calcif Tissue Int (2007) 81:183–190
DOI 10.1007/s00223-007-9050-0
Raloxifene is a selective estrogen receptor modulator
(SERM) that can bind to the estrogen receptors ERa and
ERb. It has been shown to increase BMD and reduce
vertebral fracture risk in women with postmenopausal
osteoporosis [10, 11]. In vitro studies suggest that ra-
loxifene exerts its effect, like estrogen, through modulation
of the number and activity of both osteoclasts and osteo-
blasts [12]. Kousteni et al. [13] have recently shown, using
in vitro experiments, that raloxifene does not inhibit eto-
poside-induced apoptosis of rat calvarial osteoblasts; but
no clinical studies have examined the effect of raloxifene
on osteocyte apoptosis in postmenopausal women.
In this study, we investigated whether treatment of
postmenopausal women with raloxifene for 2 years would
change osteocyte survival in trabecular bone and whether
the level of osteocyte apoptosis would be associated with
the level of bone remodeling.
Materials and Methods
Study Outline
All women in the study were participants in the Multiple
Outcomes of Raloxifene Evaluation (MORE) trial. This
was a placebo-controlled, double-blind, multicenter trial to
test the efficacy of raloxifene. Details of this study have
already been published elsewhere [10]. Briefly, 7,705
women were at least 2 years postmenopausal and had
osteoporosis as defined by a BMD of at least 2.5 standard
deviations (SDs) below the young adult mean and/or one or
more vertebral fractures. They were randomly assigned to
one of the following three treatment groups: placebo, 60
mg/day raloxifene, and 120 mg/day raloxifene. Addition-
ally, all women received daily vitamin D (400–600 IU) and
calcium (500 mg). Among the exclusion criteria for this
study were the use of androgen, calcitonin, or bisphosph-
onates within the previous 6 months; oral estrogen within
the previous 2 months; fluoride therapy for more than 3
months during the previous 2 years; or systemic gluco-
corticoid therapy for more than 1 month within the past
year. During the study the women received no therapy with
respect to their osteoporosis other than the study drugs. The
use of other prescription drugs and over-the-counter drugs
such as sedatives, antibiotics, and paracetamol was equally
distributed in the placebo and raloxifene groups.
In this study, bone biopsies were obtained at baseline
and after 2 years from 26 women who were enrolled in the
European centers of the MORE trial. These women were
part of the bone histomorphometry substudy of the MORE
trial that included 65 women from two centers in the
United States and two centers in Europe. Bone biopsies
from the other 39 women were not available for sectioning.
All women had given their informed consent, and the study
was approved by the institutional ethics review boards.
Markers of bone turnover that were measured were
serum osteocalcin, bone-specific alkaline phosphatase
(BSAP), and urinary type 1 collagen C-telopeptide cor-
rected for creatinine (CTX-I). Data are from the baseline
and 24-month evaluations.
Bone Biopsies
The women received two doses of tetracycline with a 12-
day interval. Transverse biopsy specimens were taken from
the anterior iliac crest, the 2-year biopsy being on the
opposite side from the baseline biopsy. The bone biopsies
were immediately fixed in cold 4% phosphate-buffered
formaldehyde, dehydrated in graded ethanol, and embed-
ded in methylmethacrylate (MMA; BDH Chemicals, Poole,
England) supplemented with 20% plastoid-N (Ro¨hm und
Haas, Darmstadt, Germany), 2.0 g/L benzoylperoxide
(Merck, Darmstadt, Germany), and N,N-dimethylaniline
(Merck) [14]. Sections of 5 lm were cut with a Jung
(Nussloch, Germany) K Polycut microtome. Sections were
stained with Goldner’s trichrome method. Static and
dynamic histomorphometric measurements were per-
formed as previously reported [15, 16]. Histomorphometric
indices used for this study included the percentage of bone
surface covered by osteoid (osteoid surface, OS/BS) and
the amount of mineralized bone formed per year on a given
bone area (bone formation rate/bone volume, BFR/BV) as
bone formation indices and the percentage of bone surface
covered by osteoclasts or appearing eroded (eroded sur-
face, ES/BS) and the number of osteoclasts per bone area
(osteoclast number, Ocl.N/B.Ar) as bone resorption indices
[17, 18]. Histomorphometric data and immunohistochem-
ical data were obtained from the same biopsies.
Immunohistochemistry
Apoptotic cells were visualized by immunohistochemical
detection of activated caspase-3. The antibody against
cleaved caspase-3 specifically stains apoptotic cells.
Unlike the terminal deoxynucleotidyl transferase-mediated
deoxyuridine triphosphate nick end labeling (TUNEL)
method, there is no staining of necrotic cells or cells with
DNA damage. For optimal accuracy of the method,
immunohistochemistry was performed on four 5 lm
sections of each biopsy, which were obtained with an
interval of 30 lm. Sections were cut and transferred to
poly-L-lysine-coated slides. After deplastification and
rehydration, sections were decalcified for 10 minutes with
1% acetic acid. Antigen retrieval was performed by 30-
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minute incubation with 0.5% saponin (Sigma, St. Louis,
MO) in phosphate-buffered saline (PBS) and 10-minute
incubation with 3.5 lg/mL DNAse II (Sigma) in 25 mM
Tris + 10 mM MgSO4. Sections were incubated with 3%
H2O2 in methanol to block endogenous peroxidase and
with 5% normal goat serum in PBS + 0.05% Tween to
block nonspecific binding sites. Incubation with primary
antibody was performed overnight at 4C with 1/100
rabbit-anticleaved caspase-3 antibody (Cell Signaling
Technology, Beverly, MA) in PBS + 0.05% Tween.
Sections were then incubated for 1 hour with 1/100 bio-
tin-labeled goat-anti-rabbit immunoglobulin G (Vector
Labs, Burlingame, CA) in PBS + 0.05%Tween. The
sections were incubated for 30 minutes with the ABC kit
(Vector Labs) and developed for 10 minutes with 3,30-
diaminobenzidine with nickel enhancement. Sections were
counterstained with 0.025% toluidine blue in H2O,
dehydrated, and sealed in DEPEX mounting medium
(BDH). Random quality-control sections were measured
in each assay. Sections of human ileum were tested as a
positive control for apoptotic cells.
Cell Counting
The identity of the sections was blinded, and they were
randomly numbered. In each section, the total trabecular
bone area was measured using Osteomeasure software
(Osteometrics, Atlanta, GA). In the entire trabecular bone
area, the total number of osteocytes, the number of cleaved
caspase-3-positive osteocytes, and the number of empty
lacunae were counted with x200 magnification. Artefacts,
such as areas where bone marrow obscured the trabeculae
or where trabeculae were crossed, were avoided. All sec-
tions were analyzed by the same investigator.
From these data we calculated the following parameters:
• percentage of positive osteocytes per total osteocytes
(Pos.Ot.N/Tt.Ot.N)
• percentage of empty lacunae per total lacunae (EL.N/
Tt.L.N)
• empty lacunae per bone area (EL.N/B.Ar)
• total lacunae per bone area (Tt.L.N/B.Ar)
Calculations from the four sections per biopsy were
averaged. The variation in the method was assessed by
calculating the average standard deviation from all the























in which n is number of subjects, k is number of mea-
surements per subject, nj is number of measurements in
subject j, Xij is score measurement i in subject j, and xj is
mean score in subject j.
Statistics
All values are expressed as mean ± SD. Differences in the
calculated parameters between the 2-year biopsies and the
baseline biopsies within groups were tested using a non-
parametric paired t-test (Wilcoxon signed rank test). Dif-
ferences between the treatment groups in the percent change
after 2 years of treatment were tested with a nonparametric
t-test (Mann-Whitney signed rank test). Correlations
between the calculated parameters and histomorphometric
indices or biochemical markers were assessed with Spear-
man’s rank correlations. Statistical analysis was performed
using SPSS (Chicago, IL) 12.0 software.
Results
The data presented here are derived from 26 patients who
attended the European centers of the MORE trial. There-
fore, this study covers only part of the group of patients on
which histomorphometry data were published earlier [16].
Of the 26 women in this study, 11 received placebo, ten
received 60 mg/day raloxifene, and five received 120 mg/
day raloxifene. Because the number of women in the 120
mg/day raloxifene group was small and no difference in
results between the two raloxifene treatment groups was
detected, as tested using the Mann-Whitney signed rank
test, data from the two raloxifene groups were combined
for further analysis. The average age of the women in the
placebo group was 67.9 ± 6.1 years; in the raloxifene
group the average age was 67.1 ± 6.7 years.
Staining for cleaved caspase-3 clearly identified apop-
totic osteocytes (Fig. 1a); in the negative control no cells
showed any staining. Figure 1b shows an example of an
empty lacuna. In the human ileum sections, clear positive
staining of intestinal epithelial cells was seen at the luminal
surface of the villi while the negative control showed no
staining (Fig. 1c, d). Table 1 shows the baseline and follow-
up results of the calculated parameters in the placebo group
and the raloxifene group and the average standard deviation
of the parameters. Direct comparison of the follow-up
biopsy with the baseline biopsy revealed no difference in
the percentage of positive osteocytes (Pos.Ot.N/Tl.Ot.N) in
either the placebo group or the raloxifene group.
As empty lacunae are the result of osteocyte apoptosis
and are only removed by bone remodeling, changes in the
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number of empty lacunae could be indicative of changes in
osteocyte apoptosis. In the placebo group, the percentage
of empty lacunae (EL.N/Tt.L.N) increased significantly
after 2 years (also shown in Fig. 2). The empty lacunar
density (EL.N/B.Ar) showed a parallel change, but this was
not significant. In the raloxifene group, the percentage of
empty lacunae and the empty lacunar density did not
increase significantly. The average standard deviation,
calculated from the quadruplicate analysis, showed that the
variation in the method was comparable to the variation
between individuals, except for the measurement of percent
positive cells, where the variation between the individuals
was much higher.
Associations of bone remodeling parameters with osteo-
cyte apoptosis and empty lacunae are shown in Table 2. At
baseline, in the placebo group and the raloxifene group
combined, there was a negative correlation of the histo-
morphometric indices (BFR/BV, OS/BS, ES/BS, and Ocl.N/
B.Ar) with the percent positive osteocytes (Pos.Ot.N/
Tt.Ot.N). Histomorphometric indices were not correlated
with empty lacunae. The regression lines for BFR/BV with
percent apoptotic osteocytes and percent empty lacunae are
shown in Figure 3. Correlations between biochemical indi-
ces (BSAP, osteocalcin, and CTX-1) and percent apoptotic
osteocytes or percent empty lacunae were not found.
No changes in the histomorphometric indices between
baseline and follow-up were found, nor were there any
differences between the placebo and raloxifene groups. All
three biochemical markers showed a significant decrease at
follow-up compared to baseline in the raloxifene group but
not in the placebo group (Table 3).
Discussion
We investigated the effect of treatment with raloxifene for 2
years of postmenopausal osteoporotic women on osteocyte
apoptosis as measured by activated caspase-3
Fig. 1 Immunohistochemical
staining of bone biopsy sections
and human ileum sections for
cleaved caspase-3. Human bone
biopsy sections stained with
cleaved caspase-3 (a, b).
Arrows indicate apoptotic
osteocyte (a) or empty lacuna
(b). Human ileum sections
stained with cleaved caspase-3
(c) or no first antibody (d).
Arrows indicate apoptotic cells
Table 1 Results of baseline and follow-up biopsies for the calculated parameters
Parameter (average standard deviation)a Time point Placebo (n = 11, mean ± SD) Raloxifeneb (n = 15, mean ± SD)
Pos.Ot.N/Tt.Ot.N (%) (1.28) Baseline 6.66 ± 5.28 5.30 ± 3.51
Follow-up 6.82 ± 5.27 4.99 ± 2.29
EL.N/Tt.L.N (%) (2.43) Baseline 9.00 ± 2.25 9.11 ± 2.88
Follow-up 11.20 ± 1.43c 9.74 ± 1.91
EL.N/B.Ar (n/mm2) (6.29) Baseline 21.2 ± 6.13 21.0 ± 6.49
Follow-up 24.5 ± 3.68 22.5 ± 4.67
Tt.L.N/B.Ar. (n/mm2) (22.34) Baseline 233.9 ± 28.2 231.5 ± 22.9
Follow-up 219.5 ± 27.3 231.1 ± 19.6
a Average standard deviation calculated from all quadruplicates
b The 60 mg/day and 120 mg/day raloxifene groups were combined
c Statistically significant difference (P = 0.014) from baseline value
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immunohistochemistry in iliac crest bone biopsies. Direct
comparison of follow-up with baseline in the placebo and
raloxifene groups did not show differences in the percent
positive osteocytes. This suggests that raloxifene has little or
no influence on osteocyte apoptosis. We did find a significant
increase in the percentage of empty lacunae at 2 years in the
placebo group, while there was no change in the raloxifene
group. This lack of accumulation of empty lacunae in the
raloxifene group could be the consequence of an inhibitory
effect of raloxifene on osteocyte apoptosis. At baseline,
histomorphometric indices of bone remodeling were inver-
sely correlated with apoptotic osteocytes but not with empty
lacunae. Biochemical markers of bone remodeling were not
correlated with apoptotic osteocytes or empty lacunae.
This is the first study to investigate the effect of antire-
sorptive treatment on osteocyte apoptosis in human bone
biopsies. So far, the effect of raloxifene on osteoblast or
osteocyte apoptosis has only been studied in in vitro studies.
Kousteni et al. [13] studied the effect of raloxifene on
etoposide-induced apoptosis of rat calvarial osteoblasts and
did not find protection against apoptosis. On the other hand,
Olivier et al. [19] found that raloxifene protected the
osteoblast-like cell line MC3T3-E1 against apoptosis
induced by a high concentration of nitric oxide. Comparable
clinical studies with hormone replacement therapy or bis-
phosphonates have not been published, but in vitro studies
[20, 21] and studies with mice [22, 23] have shown that both
these treatments have an inhibiting effect on osteocyte
apoptosis induced by glucocorticoids or etoposide.
The difference between the raloxifene group and the
placebo group in percent empty lacunae provides some
evidence for an inhibitory effect of raloxifene on osteocyte
apoptosis, although this effect was not reflected in the
empty lacunar density. The fact that apoptotic osteocytes
and empty lacunae change differently in response to ra-
loxifene treatment could be explained by the comparatively
short time that apoptosis can be detected. It has been shown
that nonviable osteocytes are detectable for up to 16 weeks
Fig. 2 Change in percentage empty lacunae after treatment for 2
years with either placebo (A) or raloxifene (B). Empty lacunae and
total lacunae were counted in each biopsy. The increase in the placebo
group was significant (P = 0.014)
Table 2 Association of histomorphometric indices and biochemical indices of bone remodeling with osteocyte apoptosis (Pos.Ot.N/Tt.Ot.N)
and empty lacunae (E.L.N/Tt.L.N)
Histomorphometric indices
OS/BS BFR/BV ES/BS Ocl.N/B.Ar
% Positive osteocytes (Pos.Ot.N/Tt.Ot.N) r = 0.64 r = 0.67 r = 0.48 r = 0.43
P = 0.0004a P = 0.001a P = 0.01a P = 0.03a
% Empty lacunae (E.L.N/Tt.L.N) r = 0.03 r = 0.10 r = 0.05 r = 0.48
P = 0.87 P = 0.67 P = 0.80 P = 0.02a
Biochemical indices
Osteocalcin BSAP CTX
% Positive osteocytes (Pos.Ot.N/Tt.Ot.N) r = 0.35 r = 0.43 r = 0.40
P = 0.13 P = 0.05 P = 0.09
% Empty lacunae (E.L.N/Tt.L.N) r = 0.10 r = 0.13 r = 0.31
P = 0.66 P = 0.56 P = 0.19
a Statistically significant (P < 0.05)
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[24], although remnants of apoptotic cells, such as apop-
totic bodies, might exist a little longer. Therefore, the
cleaved caspase-3-positive osteocytes that were detected
are cells that became apoptotic in the last 16 weeks of the
treatment period. Moderate changes due to treatment with
raloxifene are probably not detectable in such a short
period. Empty lacunae remain in bone until bone remod-
eling will remove them, and this period is longer then the
16 weeks that an apoptotic osteocyte is detectable.
Changes in bone remodeling could have influenced the
percentage of apoptotic osteocytes and empty lacunae that
we found. The inverse correlation between bone remodeling
indices and osteocyte apoptosis at baseline indicates that the
level of osteocyte apoptosis is indeed associated with the
level of bone remodeling. In our opinion, the explanation
for this association is that with high bone remodeling the
chance that apoptotic osteocytes are removed and replaced
by new osteocytes is also high and, therefore, the percent-
age of detected apoptotic osteocytes is low. With low bone
remodeling the chance that apoptotic osteocytes are
removed and replaced by new osteocytes is also low and,
therefore, the resulting percentage of observed apoptotic
osteocytes is high. In this way, bone remodeling partly
defines the percentage of apoptotic osteocytes, a mechanism
which has already been suggested by Dunstan et al. [25].
This dependence of the level of osteocyte apoptosis on the
level of bone remodeling complicates the detection of an
effect of a treatment on osteocyte apoptosis if that treatment
also has an effect on bone remodeling. In this study, there
were no significant effects of raloxifene on bone remodeling
parameters both in the placebo group and in the raloxifene
Fig. 3 Relationship between BFR/BV and osteocyte apoptosis at
baseline in the placebo and raloxifene groups combined. (A)
Association between BFR/BV and percent positive osteocytes.
Correlation is significant for placebo and raloxifene groups combined
(P = 0.001). (B) Association between BFR/BV and percentage empty
lacunae. No significant correlation (P = 0.67). d, placebo group; m,
raloxifene group
Table 3 Results of baseline and follow-up biopsies for histomorphometric indices and biochemical markers of bone remodeling
Parameter Time point % change Placebo (n = 11, mean ± SD) Raloxifenea (n = 15, mean ± SD)
OS/BS (%) Baseline 10.2 ± 6.8 9.9 ± 5.4
Follow-up 7.5 ± 3.2 11.6 ± 4.6
BFR/BV (%/year) Baseline 28.8 ± 20.3 35.3 ± 18.6
Follow-up 19.8 ± 8.7 23.3 ± 12.6
ES/BS (%) Baseline 5.3 ± 2.6 6.3 ± 2.9
Follow-up 5.3 ± 2.4 6.3 ± 2.4
Ocl.N./B.Ar (n/mm2) Baseline 0.6 ± 0.3 0.8 ± 0.4
Follow-up 0.6 ± 0.3 0.6 ± 0.3
BSAP (lg/L) Baseline 14.9 ± 7.3 14.4 ± 4.6
Follow-up 12.2 ± 5.6 10.0 ± 2.5b
Osteocalcin (ng/mL) Baseline 22.9 ± 10.6 25.5 ± 9.1
Follow-up 18.2 ± 3.8 16.1 ± 3.1b
CTX-1 (lg/mmol creatinine) Baseline 283.9 ± 267.0 277.4 ± 198.2
Follow-up 137.7 ± 63.8 132.3 ± 53.0b
a The 60 mg/day and 120 mg/day groups were combined
b Significantly different from baseline (P < 0.05)
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group; however, changes in individual women over the 2-
year treatment period could have influenced the level of
osteocyte apoptosis found at follow-up. This could have
obscured detection of a possible effect of raloxifene on
osteocyte apoptosis.
The inverse correlation between osteocyte apoptosis and
bone remodeling seems to be in contrast with the hypoth-
esis put forward by several investigators [5, 26] that viable
osteocytes inhibit bone remodeling and that lack of viable
osteocytes, e.g., near sites of microdamage, attracts bone
remodeling. We believe that our results do not contradict
this hypothesis. Attraction of osteoclasts by dead osteo-
cytes or by lack of osteocytes is probably a local process. If
the occurrence of dead osteocytes and empty lacunae
stimulates bone remodeling, the lacunae are more quickly
removed and replaced with viable osteocytes.
The percent empty lacunae was not correlated to histo-
morphometric indices of bone remodeling. This suggests
that the empty lacunae for a large part exist and increase in
number in bone that is not participating in remodeling. In
two studies, Qiu et al. [27, 28] have made the distinction
between superficial bone and deep bone, i.e., bone at the
surface of trabeculae and bone in the center of trabeculae.
They postulated that deep bone is remodeled much more
slowly than superficial bone. In this study, we did not make
a distinction between superficial bone and deep bone, but it
is possible that the increase in empty lacunae that we found
primarily occurred in deep bone.
Biochemical markers of bone formation and resorption
were not correlated with osteocyte apoptosis or with empty
lacunae. Biochemical markers reflect bone remodeling in
the whole skeleton, both in trabecular bone and in cortical
bone. Correlations between such general markers and
parameters measured locally in trabecular bone of the iliac
crest are possibly more difficult to find.
The major limitation of our study is the small number of
patients. The percentage of apoptotic osteocytes varied
considerably between individuals, and this makes it diffi-
cult to find significant differences between such small
groups. The variation was not caused by variation in the
method, as shown by the low average standard deviation,
indicating that the percentage of apoptotic osteocytes has to
be an individual characteristic.
Detection of cleaved caspase-3, a key protease in the
apoptotic process, is an established method for measuring
apoptosis [29, 30]; and it has recently been used on bone
tissue [31]. In the latter study, comparison between the
TUNEL method and the cleaved caspase-3 method showed
no significant differences. We confirmed the specificity of
the detection of cleaved caspase-3 in sections of human
ileum. In these sections, only the cells which are expected
to be apoptotic [32] were stained by our method. Necrotic
death of osteocytes might also occur in bone; however, we
expect that necrotic cell death is low and not responsive to
interventions such as estrogen, glucocorticoids, or
mechanical loading. The average percentage apoptotic os-
teocytes we found was somewhat lower than what Tom-
kinson et al. [8] found in their study in young women who
had received gonadotropin-releasing hormone analogue
therapy. This could reflect differences in age and in treat-
ment between the two studies.
The number of empty lacunae that we observed could be
an overestimation caused by sectioning artefacts or the
decalcification step in the immunohistochemistry method.
We do not know to what extent this occurs, but this would
be equal in all biopsies. Goldner-stained sections showed
more sectioning artefacts, and therefore, empty lacunae in
these sections were not counted. Inconsistency between the
change in percent empty lacunae and empty lacunar density
in the placebo group is probably also related to the small
number of patients studied.
In this study, we did not find clear evidence that treat-
ment with raloxifene influences osteocyte apoptosis. No
change in the percentage of apoptotic osteocytes was
detected, while the changes in the empty lacunae were
inconclusive and at best indirect evidence that osteocyte
apoptosis had been changed by raloxifene. Compared to
estrogen, raloxifene treatment shows a similar reduction of
vertebral fractures (but not nonvertebral fractures) [10, 33]
but has less potent positive effects on bone quality assessed
by BMD measurement and bone histomorphometry [34,
35]. It is conceivable that the weaker effect of raloxifene on
bone is related to only a weak antiapoptotic effect or lack
of antiapoptotic action. This is, however, difficult to mea-
sure in a study with such a small number of subjects. It
would be of interest to compare the effects of different
antiresorptive treatments on osteocyte apoptosis in larger
clinical studies and to compare the mechanisms by which
they exert their effect.
In conclusion, we did not find evidence for an effect of
raloxifene treatment on osteocyte apoptosis in postmeno-
pausal women, but small effects of raloxifene treatment on
osteocyte apoptosis cannot be excluded. The percent of
apoptotic osteocytes was dependent on the level of bone
remodeling in an individual.
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